Abstract
The aim of the present paper is to address the legal aspects, technical requirements and possible conditions of use associated to low molecular weight heparin generics and biosimilars that are arriving to the market in United States and the European Union, respectively. To this end the concept of “similar biological medicinal product” that was coined in 2003 by the pharmaceutical legislation of the European Union is compared to the concept of generic in the United States and the concept of generic in the European Union. This different legal basis determines directly the technical requirements to obtain a marketing authorisation. Therefore, the chemical/biological, non-clinical and clinical requirements to demonstrate therapeutic equivalence are different in these two Regulatory Authorities, FDA and EMA. Consequently, the possible conditions of use are different. In the United States the products approved as generics by the FDA are considered interchangeable to the Reference Listed Drug. In contrast, the EMA legislation only deals with the approvability or prescribability of the medicines and it is a national / regional decision of the member States to consider these biosimilar products as interchangeable or not.
Keywords: Bioequivalence, biosimilars, generic, interchangeability, low molecular weight heparins, regulatory science
Current Drug Discovery Technologies
Title:Regulatory Considerations for Generic or Biosimilar Low Molecular Weight Heparins
Volume: 9 Issue: 2
Author(s): Alfredo Garcia-Arieta and Antonio Blazquez
Affiliation:
Keywords: Bioequivalence, biosimilars, generic, interchangeability, low molecular weight heparins, regulatory science
Abstract: The aim of the present paper is to address the legal aspects, technical requirements and possible conditions of use associated to low molecular weight heparin generics and biosimilars that are arriving to the market in United States and the European Union, respectively. To this end the concept of “similar biological medicinal product” that was coined in 2003 by the pharmaceutical legislation of the European Union is compared to the concept of generic in the United States and the concept of generic in the European Union. This different legal basis determines directly the technical requirements to obtain a marketing authorisation. Therefore, the chemical/biological, non-clinical and clinical requirements to demonstrate therapeutic equivalence are different in these two Regulatory Authorities, FDA and EMA. Consequently, the possible conditions of use are different. In the United States the products approved as generics by the FDA are considered interchangeable to the Reference Listed Drug. In contrast, the EMA legislation only deals with the approvability or prescribability of the medicines and it is a national / regional decision of the member States to consider these biosimilar products as interchangeable or not.
Export Options
About this article
Cite this article as:
Garcia-Arieta Alfredo and Blazquez Antonio, Regulatory Considerations for Generic or Biosimilar Low Molecular Weight Heparins, Current Drug Discovery Technologies 2012; 9 (2) . https://dx.doi.org/10.2174/1570163811209020137
DOI https://dx.doi.org/10.2174/1570163811209020137 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Endocannabinoids in Pain Modulation and the Therapeutic Potential of Inhibiting their Enzymatic Degradation
Current Pharmaceutical Biotechnology Chemokines and Malaria Infection
Current Immunology Reviews (Discontinued) Application of Contemporary Neuroproteomic Techniques in Unravelling Neurological Disorders
Current Protein & Peptide Science Renin-Angiotensin System in Central Nervous System Diseases and its Interaction with COVID-19
Current Medicinal Chemistry Respiratory Stem Cells and Progenitors: Overview, Derivation, Differentiation, Carcinogenesis, Regeneration and Therapeutic Application
Current Stem Cell Research & Therapy A Study of Correlation between Anti-peroxidative Potential of Quercetin and Ascorbic Acid with Malondialdehyde by RP-HPLC
Current Chemical Biology Pharmacological Innovations for Posttraumatic Stress Disorder and Medication- Enhanced Psychotherapy
Current Pharmaceutical Design Exploring New CGRP Family Peptides and their Receptors in Vertebrates
Current Protein & Peptide Science Recent Advances in Pathophysiology of Traumatic Brain Injury
Current Neuropharmacology Novel Anti-Cancer Strategy in Bone Tumors by Targeting Molecular and Cellular Modulators of Bone Resorption
Recent Patents on Anti-Cancer Drug Discovery Agonists of the Tissue-Protective Erythropoietin Receptor in the Treatment of Parkinson’s Disease
Current Topics in Medicinal Chemistry Neurological Involvement in Rheumatoid Arthritis
Current Immunology Reviews (Discontinued) Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery Plasma Infusions into Porcine Cerebral White Matter Induce Early Edema, Oxidative Stress, Pro-Inflammatory Cytokine Gene Expression and DNA Fragmentation: Implications for White Matter Injury with Increased Blood- Brain-Barrier Permeability
Current Neurovascular Research The Role of Oligodendrocytes in the Molecular Pathobiology and Potential Molecular Treatment of Cervical Spondylotic Myelopathy
Current Medicinal Chemistry Mechanisms of Oxidative Glutamate Toxicity: The Glutamate/Cystine Antiporter System xc¯ as a Neuroprotective Drug Target
CNS & Neurological Disorders - Drug Targets Current Management of Traumatic Rupture of the Descending Thoracic Aorta
Current Cardiology Reviews Physiological and Pathological Functions of Acid-Sensing Ion Channels in the Central Nervous System
Current Drug Targets Stem Cell-Based Approaches for Intervertebral Disc Regeneration
Current Stem Cell Research & Therapy The Extra-Hematopoietic Role of Erythropoietin in Diabetes Mellitus
Current Diabetes Reviews